Mackenzie Financial
NGM

Mackenzie Financial’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Mackenzie Financial’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-62,964
Closed -$54.1K – 1627
2023
Q4 		$54.1K Buy
62,964
+18,084
+40% +$15.9K ﹤0.01% 1443
2023
Q3 		$53.9K Buy
44,880
+25,788
+135% +$53.4K ﹤0.01% 1408
2023
Q2 		$51.5K Buy
19,092
+6,309
+49% +$22.5K ﹤0.01% 1457
2023
Q1 		$52.2K Buy
+12,783
New +$59.1K ﹤0.01% 1441

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Mackenzie Financial's NGM Position: Q1 2024 in Review

Mackenzie Financial sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q1 2024, closing a stake of 62,964 shares — an estimated $54.1K sold.

Mackenzie Financial first reported a position in NGM in Q1 2023 and held it in 4 quarters. The position peaked at $54.1K in Q4 2023. 75 funds tracked by Wall St. Rank hold NGM as of Q1 2024.

  • Mackenzie Financial reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Mackenzie Financial sold 62,964 NGM Biopharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $54.1K.
  • Mackenzie Financial first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2023 and held it in 4 quarters.
  • Mackenzie Financial's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $54.1K in Q4 2023.
  • 75 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Mackenzie Financial's 13F filing for Q1 2024, filed 10 May 2024.